抗肿瘤靶向和免疫治疗致银屑病研究进展

Psoriasis induced by anti-tumor targeted therapy and immunotherapy

近年来靶向和免疫治疗在抗肿瘤治疗中的应用越来越广,不断有此类药物引起或加重银屑病的报道。该文根据药物的作用靶点与可能机制,总结与评价诱发或加重银屑病的相关药物,包括程序性死亡受体1抑制剂、表皮生长因子受体抑制剂、人表皮生长因子受体2抑制剂、CD20单抗、磷脂酰肌醇3激酶δ抑制剂以及多靶点药物。多数病例银屑病发生与药物可能或很可能相关,仅少数存在明确的因果关系。

In recent years,targeted therapy and immunotherapy have been applied more and more widely in tumor treatment,and reports on psoriasis induced or exacerbated by these drugs have emerged continuously.This review summarizes and evaluates targeted therapeutic drugs and immunotherapeutic drugs that allegedly induce or aggravate psoriasis according to their targets and possible mechanisms,including programmed death receptor 1 inhibitors,epidermal growth factor receptor inhibitors,human epidermal growth factor receptor 2 inhibitors,anti-CD20 monoclonal antibodies,phosphoinositide 3-kinaseδinhibitors and multi-targeted drugs.In most cases,the relationships between drugs and the occurrence of psoriasis are possible or probable,and in only a few cases the causality is certain.